论文部分内容阅读
目的研究分析长期吸入小剂量布地奈德对哮喘患儿骨密度的影响。方法 80例哮喘患儿作为观察组,随机分为A、B两组,各40例,所有患儿均给予长期吸入布地奈德治疗,剂量分别为100μg、150μg,持续时间为9~12个月,再选取40例正常体检儿童作为对照组。对比分析观察组A、B两组患儿临床治疗效果。结果所有患儿临床治疗总有效率均为100.0%;治疗后骨密度指标与治疗开始时及正常儿童相比,差异无统计学意义(P>0.05)。结论长期吸入小剂量布地奈德对于哮喘患儿具有较高临床应用价值,疗效确切,不影响哮喘患儿骨密度,值得临床大力推广。
Objective To study the effect of long-term inhaled low-dose budesonide on bone mineral density in asthmatic children. Methods Eighty asthmatic children were randomly divided into two groups (A and B), 40 in each. All children were given long-term inhalation of budesonide at doses of 100 μg and 150 μg, respectively, for a duration of 9 to 12 months , Then select 40 normal children as control group. Comparative analysis of the observation group A, B two groups of children with clinical treatment. Results The total effective rate of clinical treatment in all children was 100.0%. There was no significant difference in BMD between treatment and normal children (P> 0.05). Conclusion Long-term inhalation of low-dose budesonide has a high clinical value for children with asthma. The curative effect is exact, does not affect the bone mineral density in children with asthma, and is worth promoting clinically.